Is OPCH a good stock to buy?
We came across a bullish thesis on Option Care Health, Inc. on r/ValueInvesting by Unusual_Reveal_8569
In this article, we will summarize the bulls’ thesis on OPCH. Option Care Health, Inc.’s share was trading at $21.99 as of June 18th. OPCH’s trailing and forward P/E were 17.16 and 12.35 respectively according to Yahoo Finance.
Option Care Health (OPCH) is the largest independent provider of home and alternate-site infusion services in the United States, operating a high-quality healthcare platform anchored in chronic infusion therapies, immunoglobulin treatments, and anti-infective medications, with strong payer integration and structurally sticky patient demand driven by the preference for at-home care versus hospital settings. 15 AI Stocks That Are Quietly Making Investors Rich Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential The company has recently generated quarterly revenues in the $1.3–1.4 billion range, maintains approximately 2x net leverage, and delivers mid-to-high single digit EBITDA margins with forward guidance improving toward ~8.5 percent, reflecting underlying operational stability despite near-term volatility. A sharp Q1 2026 revenue miss and roughly 30 percent share price decline were driven primarily by Stelara biosimilar disruption within chronic inflammatory disease, where high-margin infusion volumes were unexpectedly displaced by self-administered alternatives, creating a market perception of structural demand erosion in a key profit pool. However, the core investment thesis argues this dislocation is largely cyclical in the medium term, as meaningful additional biosimilar or self-administration substitution risk across OPCH’s broader molecule portfolio is limited until late 2027 to 2028, with most therapies exhibiting either slow transition dynamics or low economic impact.